All Posts Tagged With: "ABAX"
(ABAX) Abaxis Analyst Upgrades Shares to Neutral
Following the company’s solid second quarter 2011 results, which were ahead of the Zacks Consensus Estimates, we have upgraded our recommendation on Abaxis (ABAX) to Neutral with a target price of $26.00.
The...
(ABAX) Alere Takes Over Arriva Medical
Alere (ALR), a medical products company focused on integrating rapid diagnostics with health management, recently revealed that it has taken over Arriva Medical, a prominent vendor of diabetes testing supplies...
(ABAX) Alere Quarterly Earnings Beats Estimates
Alere (ALR), a medical products company focused on integrating rapid diagnostics with health management, reported first-quarter fiscal 2011 adjusted earnings per share of 61 cents, beating the corresponding...
(ABAX) Abaxis Analyst Maintains Neutral Rating
We recently reiterated our ‘Neutral’ rating on Abaxis, Inc. (ABAX) with a target price of $28, based on a P/E of 34.1x our fiscal 2011 EPS estimate of 82 cents. Abaxis’ results for the third quarter...
(ABAX) Abaxis Thurd Quarter 2010 Report Misses Estimates
Abaxis, Inc. (ABAX) reported third quarter fiscal 2010 earnings per share of 15 cents, missing the Zacks Consensus Estimate of 17 cents. However, earnings in the year-ago quarter were 15 cents.
Sales
(ABAX) Abaxis Receives FDA Approval
Abaxis, Inc. (ABAX) recently received the U.S. Food and Drug Administration (FDA) approval to market its new C-Reactive Protein (CRP) assay in the United States. The new C-Reactive Protein assay is used by...
(ABAX) Abaxis Launches New Bird Flu Test Product
Abaxis, Inc. (ABAX) reported that it has launched its first product, a rapid Avian Influenza Antigen Test, in the production animal diagnostics market. Avian Influenza Antigen Test is a disposable and USDA-licensed...
(ABAX) Abaxis Earnings Report Lags Consensus Estimates
Abaxis Inc. (ABAX) reported second quarter fiscal 2010 earnings per share of 14 cents, lower than the Zacks Consensus Estimate of 17 cents and the year-ago earnings of 15 cents.